Pembrolizumab is more effective than chemotherapy in selected patients with colorectal cancer

MSD presented the results of the study, KEYNOTE-177, which pembrolizumab was used as first-line therapy in patients with inoperable or metastatic colorectal cancer with high level microsatellite instability (MSI-H) or disturbances in the DNA repair system (dMMR). The study shows that monotherapy ambrosianeum reduced the risk of disease progression or death by 40 % (RR = 0,60 [95 % CI; 0,45–0,80; p = 0,0002]) and provided a median survival without progression (VBP) of 16.5 months, compared with 8.2 months in the use of chemotherapy (at the choice of the researcher: mFOLFOX6 or FOLFIRI in combination with bevacizumab or cetuximab), which is the standard therapy in such patients. The study will continue to assess overall survival (OS) – second primary endpoint.

The safety profile of ambrosianae demonstrates a low incidence of adverse events (AES) ≥ grade 3 severity related to treatment, compared to chemotherapy (22% versus 66 %, respectively), thus a new AES was not observed. Immune-mediated AES and infusion reactions was observed in 31% of patients in the treatment group ambrosianeum, and 13 % of patients in the chemotherapy group. The most common immune-mediated adverse events in the treatment group ambrosianeum was hypothyroidism (12 %) and colitis (7 %), and in the group of chemotherapy – infusion reaction (8 %).

In may 2017 pembrolizumab became the first anticancer drug that was approved by the FDA for the treatment of patients with any type of malignant tumors with MSI-H or dMMR after prior systemic therapy.

Leave a Reply

Your email address will not be published. Required fields are marked *


For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]